Multi Protein Nanoparticle Monkeypox Vaccine
In 2022, the World Health Organization declared an atypical outbreak of monkeypox (Mpox), which has caused approximately 30,000 cases of Mpox infection within the United States as of April 2023. Mpox represents a current threat to public health, and there is an immediate need for an effective vaccine. To address this, NIAID has developed a vaccine approach comprising virus-like nanoparticles coated with modified Mpox proteins.
Francisella Lipids as Broad Anti-inflammatory Therapeutics
Anti-inflammatory treatments, particularly those used in the context of viral infection, have been shown to greatly inhibit the overall immune response, which can result in poor immunity and failure to control or clear the infection. Novel alternatives that can effectively attenuate inflammation without the more serious side effects of steroid medications (e.g., global immune suppression, muscle weakness, etc.) may have substantial use across a wide range of disease areas.
The Use of alpha-4 beta-7 integrin Inhibitors to Inhibit HIV Transmission and Infection
Broadly Neutralizing Human Anti-HIV Monoclonal Antibody 10E8 and Related Antibodies Capable of Neutralizing Most HIV-1 Strains
Dual-Germline Antibody Engager Chimeric HIV–1 Immunogens
Despite four decades of intensive research, a safe and effective HIV-1 vaccine remains elusive due to the extreme difficulty in eliciting broadly neutralizing antibodies (bNAbs), which recognize and block HIV-1 from entering healthy cells. Only rare natural HIV-1 envelopes (Envs) promote the activation and expansion of naive B cells expressing unmutated germline antibodies of various bNAb lineages, but they typically do so for a single lineage for the same neutralization site.
Human Monoclonal Antibodies to Generate Chimeric Antigen Receptor (CAR) T-cells to Treat Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC).
This technology includes six human monoclonal antibodies (mAbs) that target tumor antigens derived from the CT-RCC HERV-E (human endogenous retrovirus type E) to generate Chimeric Antigen Receptor (CAR) T cells to treat patients with advanced clear cell renal cell carcinoma (ccRCC). These mAbs were identified from Adagene Inc’s human antibody phage library, and data show that majority of these mAbs only bind to CT-RCC HERV-E+ ccRCC cells, which express TM but not CT-RCC HERV-E non-expressing ccRCC cells nor non-RCC cells.
Antibody to Mitochondrial Uniporter (MCU
This technology includes a generated polyclonal antibody in rabbit that detects the mitochondrial uniporter (MCU) protein. This antibody was created by immunizing rabbits with a synthesized sequence of the MCU protein and can be used to identify and quantify MCU protein in various tissues. The polyclonal nature of the antibody ensures it recognizes multiple epitopes on the MCU, enhancing detection reliability. This technology is crucial for understanding MCU's role in mitochondrial function and mammalian physiology.
Enhanced S10-3 Cell Line for Advanced Hepatitis E Virus Research and Therapeutic Development
The Huh-7 cell line underwent a detailed sub-cloning process to enhance its effectiveness for Hepatitis E Virus (HEV) infection studies. This involved diluting and culturing cells in 96-well plates until confluent monolayers formed, followed by selection and expansion of the most suitable cells. The sub-clone S10-3, derived from this process, was identified as the most efficient for transfection and infection by HEV.
Antibodies to TMC1 Protein for Hearing Loss
This technology includes antibodies for TMC1 protein as a treatment for hearing loss. TMC1 is one of the common genes causing hereditary hearing loss. Our laboratory used synthetic peptides corresponding to the TMC1 protein to immunize rabbits. The resulting antisera were shown to bind to TMC1 protein expressed in heterologous expression systems. TMC1 protein is required for the transduction of sound into electrical impulses in inner ear sensory cells.